{
  "ticker": "BGT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968788",
  "id": "02968788",
  "pages": 37,
  "price_sensitive": false,
  "date": "20250711",
  "time": "1759",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250711/pdf/06lqr36kj6l5yc.pdf",
  "summary": "### **Material Information Summary (Options Prospectus - Bio-Gene Technology Limited)**  \n\n#### **1. Offer Structure**  \n- **Type**: Options issuance (Placement Options attached to Placement Offer).  \n- **Total Options Offered**: 95,352,788 (split equally between two tranches):  \n  - **2028 Options**: 47,676,394 (exercise price: **A$0.034**; expiry: **15 May 2028**).  \n  - **2030 Options**: 47,676,394 (exercise price: **A$0.046**; expiry: **15 May 2030**).  \n- **Allocation**:  \n  - **Placement Participants**: 92,302,176 Options (1x 2028 + 1x 2030 Option per 2 Placement Shares subscribed).  \n  - **Lead Manager (Stralis Capital)**: 3,050,612 Options (1,525,306 of each tranche).  \n\n#### **2. Key Conditions & Timetable**  \n- **Condition**: Shareholder approval required (via EGM on **14 July 2025**).  \n- **Expected Issue Date**: **15 July 2025** (within 5 days of EGM approval).  \n- **Other Dates**:  \n  - Prospectus lodgment: **11 July 2025**.  \n  - Holding statements dispatched: **16 July 2025**.  \n\n#### **3. Financial Impact**  \n- **No Immediate Capital Raised**: Options issued for no additional cash consideration.  \n- **Potential Future Proceeds**: If all options exercised:  \n  - **2028 Options**: ~A$1.62M (47.7M \u00d7 A$0.034).  \n  - **2030 Options**: ~A$2.19M (47.7M \u00d7 A$0.046).  \n  - **Total**: ~A$3.8M (pre-costs).  \n\n#### **4. Dilution & Control**  \n- **Current Shares Outstanding**: 266,419,324.  \n- **Max Dilution (if all Options exercised)**: ~23.6% (excluding SPP Options).  \n- **No Single Holder**: Expected post-issue voting power <20% for any entity.  \n\n#### **5. Key Risks**  \n- **Market & Liquidity**: Options are **not quoted on ASX**; secondary sales restricted.  \n- **Valuation**: Exercise prices ($0.034/$0.046) may exceed future market price.  \n- **Commercialization Risks**: Reliance on insecticide development (Flavocide/Qcide), regulatory hurdles, and funding needs.  \n\n#### **6. Other Material Details**  \n- **Use of Funds (if exercised)**: General working capital (no specific allocation).  \n- **Tax/Legal**: No material litigation; Directors hold minimal shares (<5% collectively).  \n\n**No other material information identified.**  \n\n---  \n**Note**: Omitted boilerplate, risk disclaimers, and non-trading/capital structure details. Focused on actionable data for investors.",
  "usage": {
    "prompt_tokens": 18080,
    "completion_tokens": 648,
    "total_tokens": 18728,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-11T09:26:21.509837"
}